Dr. John Cush RheumNow
1 year 3 months ago
What we need in very early arthritis
It's easy to think that in our current world that we've done it all for rheumatoid arthritis, that there's nothing left to be done after b/tsDMARDs have become relatively widespread and accessible. If we aren’t satisfied that we’ve done all https://t.co/v8T3JQwuhM
Dr. John Cush RheumNow
1 year 3 months ago
Korean Health claims data study of 35,133 newly Dx, seropositive #RA pts (2011 to 2020) & 1,386 (3.9%) were Dx w/ new-onset stroke (CVA). Signif. lower risk of CVA w/ SSZ (aOR: 0.79) or HCQ (aOR: 0.83), but Increased risk w/ glucocorticoids (aOR: 1.71) & tocilizumab (aOR: 3.47) https://t.co/rPaj6cH74K
Dr. John Cush RheumNow
1 year 3 months ago
Using Veterans Affairs data (2006 - 2020) on RA-ILD patients, a target emulation trial showed no difference in mortality or respiratory hospitalization comparing RA-ILD Rx w/ either RTX, abatacept, tocilizumab, tofacitinib. Does this mean? they Dont Work or the Do Work? https://t.co/MkQmKsE3WQ
Dr. John Cush RheumNow
1 year 3 months ago
What would it take for JAKs to ROCK the boat?
JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. https://t.co/tgfsU3uFVo
A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes.A systematic review included 102 studies and 340 patients with icGCA. The median age was 73.7 years with 47% patients being female.
Dr. John Cush RheumNow
1 year 3 months ago
post hoc MRI study from Osteoarthritis Initiative (OAI) of 210 knee OA pts (mean age 64) Rx w/ either IA corticosteroids or hyaluronate (HA). Bboth reduced pain post-injx (WOMAC -5.2 CS & -2.1 HA), CS had worse progression (cartilage, BM lesions, meniscus) vs controls & HA https://t.co/pbb1ePXob1
Dr. John Cush RheumNow
1 year 3 months ago
Upcoming Lupus Nephritis Pipeline
1. Gazyva (obinutuzumab) – due for FDA/EMA decision
2. Saphnelo IV (anifrolumab) – now in Phase III (new indication for LN
3. Ianalumab SC (Dual-action B-cell inhibitor) – now in Phase III https://t.co/mTInV8JXzq https://t.co/3qg1FWzZRI
Dr. John Cush RheumNow
1 year 3 months ago
Lichenoid rash vs SCLE? JAMA Dermatology case - 60yoM w/ https://t.co/xl11CwB1AJ problems & meds has pink-red papules (central hypopigmentation) on arms, chest, back (no fungus). Bx= lichenoid dermatitis. Rash worsened, red & annular; Dx now SCLE +ANA/Ro/La) from diltiazem. SCLE
Dr. John Cush RheumNow
1 year 3 months ago
Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases
During the Late-Breaking Abstract session at EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD).
https://t.co/5bjyaqTqSN https://t.co/i4mGMYfyNK
Dr. John Cush RheumNow
1 year 3 months ago
National Psoriasis Found. Consensus Defines On-Treatment Remission in Plaque Psoriasis as 0% BSA and MD global=0 for at least 6 months while on treatment. For both clinical practice and clinical trials. https://t.co/QJg0ZIQ5Mv https://t.co/0FnbFcpXQB
Dr. John Cush RheumNow
1 year 3 months ago
Survey shows only 1% of men are concerned about bone density; but 2 million men have osteoporosis, and 16 million men have osteopenia. https://t.co/DA4vSmj0vd? https://t.co/V4OChN022V
Dr. John Cush RheumNow
1 year 3 months ago
Increasing costs of biologics. X-sectional study of 76 781 psoriasis pts on biologics (TNFi, IL12/23, IL-17i, IL-23i) saw annual treatment cost increase from $21 236 in 2007 to $47 125 in 2021. AVG cost could have been 44% lower if lowest-cost Rx in same class was used https://t.co/IOaK75zsgg
Dr. John Cush RheumNow
1 year 3 months ago
By March 2025, the FDA has approved 71 biosimilars (15 interchangeable). The US & EU biosimilars markets spent $22.58 billion in 2024 & is projected to increase by 25% to $171.79 billion by 2033 https://t.co/fsqGTzWuhC https://t.co/ZLYSIwRqI4
